Product Code: GVR-4-68038-554-0
Fluorescein Angiography Market Growth & Trends:
The global fluorescein angiography market size is expected to reach USD 1.39 billion by the end of 2030, expanding at a CAGR of 8.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of ophthalmic conditions such as macular degeneration and diabetic retinopathy and rapid technological advancements are some of the high impact-rendering market drivers. However, the growing preference for safer and faster alternatives such as OCT and fundus autofluorescence is anticipated to impede market growth during the forecast period.
End-users such as hospitals and imaging centers in the country are effectively adopting AI-based fundus cameras for detecting various blindness-causing diseases. For instance, in January 2019, Deqing County hospital in Guangdong Province conducted a free consultation by featuring an AI camera codeveloped by Sun Yat-sen University and Baidu-a multinational technology company in China that offers services, including a search engine platform-to detect ocular fundus diseases. This AI fundus camera is capable of diagnosing glaucoma, diabetic retinopathy, and macular degeneration.
Despite preference of its alternatives, fluorescein angiography is often used as confirmatory test for a wide range of ophthalmic conditions. The technique provides accurate and high quality pictures which help in selecting efficient treatment regimen. In addition, the demand for tradition fluorescein angiography systems is still high in developing countries. This can be attributed to affordability and product availability.
Fluorescein Angiography Market Report Highlights:
- Traditional fluorescein angiography dominated the market and accounted for the largest revenue share of 56.4% in 2024, attributed to the rising incidence of eye diseases, particularly diabetic retinopathy and age-related macular degeneration.
- The age-related macular degeneration (AMD) application held the dominant position in the market, with the largest revenue share of 32.6% in 2024, owing to the increasing prevalence of this condition among the aging population.
- The hospitals and clinics segment led the market and accounted for the largest revenue share of 63.9% in 2024 attributed to the increasing prevalence of eye diseases, particularly among the aging population.
- The fluorescein angiography market in North America dominated the global market and accounted for the largest revenue share of 36.4% in 2024 attributed to the high prevalence of eye diseases, particularly diabetic retinopathy, which affects millions of individuals.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. End Use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Fluorescein Angiography Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
Chapter 4. Fluorescein Angiography Market: Type Business Analysis
- 4.1. Type Market Share, 2024 & 2030
- 4.2. Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 4.4. Traditional Fluorescein Angiography (FA)
- 4.4.1. Traditional Fluorescein Angiography (FA) Market, 2018 - 2030 (USD Million)
- 4.5. Confocal Scanning Laser Ophthalmoscopy (cSLO) FA
- 4.5.1. Confocal Scanning Laser Ophthalmoscopy (cSLO) FA Market, 2018 - 2030 (USD Million)
Chapter 5. Fluorescein Angiography Market: Application Business Analysis
- 5.1. Application Market Share, 2024 & 2030
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Age-related Macular Degeneration (AMD)
- 5.4.1. Age-related Macular Degeneration (AMD) Market, 2018 - 2030 (USD Million)
- 5.5. Diabetic Retinopathy
- 5.5.1. Diabetic Retinopathy Market, 2018 - 2030 (USD Million)
- 5.6. Retinal Vein Occlusion
- 5.6.1. Retinal Vein Occlusion Market, 2018 - 2030 (USD Million)
- 5.7. Uveitis and Retinal Vasculitis
- 5.7.1. Uveitis and Retinal Vasculitis Market, 2018 - 2030 (USD Million)
- 5.8. Choroidal Tumors
- 5.8.1. Choroidal Tumors Market, 2018 - 2030 (USD Million)
- 5.9. Others
- 5.9.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Fluorescein Angiography Market: End Use Business Analysis
- 6.1. End Use Market Share, 2024 & 2030
- 6.2. End Use Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 6.4. Hospitals and Clinics
- 6.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
- 6.5. Ambulatory Surgical Centers
- 6.5.1. Ambulatory Surgical Centers Market, 2018 - 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Fluorescein Angiography Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Regulatory Framework
- 7.4.2.3. Competitive Insights
- 7.4.2.4. U.S. Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Regulatory Framework
- 7.4.3.3. Competitive Insights
- 7.4.3.4. Canada Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Regulatory Framework
- 7.4.4.3. Competitive Insights
- 7.4.4.4. Mexico Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Regulatory Framework
- 7.5.2.3. Competitive Insights
- 7.5.2.4. UK Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Regulatory Framework
- 7.5.3.3. Competitive Insights
- 7.5.3.4. Germany Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Regulatory Framework
- 7.5.4.3. Competitive Insights
- 7.5.4.4. France Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Regulatory Framework
- 7.5.5.3. Competitive Insights
- 7.5.5.4. Italy Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Regulatory Framework
- 7.5.6.3. Competitive Insights
- 7.5.6.4. Spain Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Norway
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Regulatory Framework
- 7.5.7.3. Competitive Insights
- 7.5.7.4. Norway Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Regulatory Framework
- 7.5.8.3. Competitive Insights
- 7.5.8.4. Denmark Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Sweden
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Regulatory Framework
- 7.5.9.3. Competitive Insights
- 7.5.9.4. Sweden Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Regulatory Framework
- 7.6.2.3. Competitive Insights
- 7.6.2.4. Japan Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Regulatory Framework
- 7.6.3.3. Competitive Insights
- 7.6.3.4. China Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Regulatory Framework
- 7.6.4.3. Competitive Insights
- 7.6.4.4. India Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Regulatory Framework
- 7.6.5.3. Competitive Insights
- 7.6.5.4. South Korea Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Regulatory Framework
- 7.6.6.3. Competitive Insights
- 7.6.6.4. Australia Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Regulatory Framework
- 7.6.7.3. Competitive Insights
- 7.6.7.4. Thailand Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Regulatory Framework
- 7.7.2.3. Competitive Insights
- 7.7.2.4. Brazil Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Regulatory Framework
- 7.7.3.3. Competitive Insights
- 7.7.3.4. Argentina Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. MEA Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Regulatory Framework
- 7.8.2.3. Competitive Insights
- 7.8.2.4. South Africa Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Regulatory Framework
- 7.8.3.3. Competitive Insights
- 7.8.3.4. Saudi Arabia Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Regulatory Framework
- 7.8.4.3. Competitive Insights
- 7.8.4.4. UAE Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Regulatory Framework
- 7.8.5.3. Competitive Insights
- 7.8.5.4. Kuwait Fluorescein Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Carl Zeiss Meditec, Inc.
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Type Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. NIDEK Co., Ltd.
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Type Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Kowa Company Ltd.
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Type Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Topcon Medical Systems, Inc.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Type Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Optomed Oy (Ltd.)
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Type Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. CenterVue SpA
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Type Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Canon, Inc.
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Type Benchmarking
- 8.5.7.4. Strategic Initiatives